138851-30-6

Basic information

• Product Name: Benzoic acid, 5-(2,2-dicyanoethenyl)-2-hydroxy-
• Synonyms: Benzoic acid,5-(2,2-dicyanoethenyl)-2-hydroxy;5-(2,2-dicyanoethenyl)salicylic acid;5-(2,2-dicyanoethen-1-yl)-2-hydroxybenzoic acid
• CAS NO: 138851-30-6
• Molecular Formula: C11H6N2O3
• Molecular Weight: 214.18
• Mol File: 138851-30-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 458.5±45.0 °C(Predicted)
• Density: 1.482±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzoic acid, 5-(2,2-dicyanoethenyl)-2-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-(2,2-dicyanoethenyl)-2-hydroxy-(138851-30-6)
• EPA Substance Registry System: Benzoic acid, 5-(2,2-dicyanoethenyl)-2-hydroxy-(138851-30-6)

Safety Data

• Hazardous Substances Data: 138851-30-6(Hazardous Substances Data)

Upstream product

• 616-76-2 2-hydroxy-5-formylbenzoic acid 
• 109-77-3 malononitrile 
• 100-46-9 benzylamine 

Downstream Products

• 138851-40-8 2-phenyl-4-(5-salicylyl)-6-amino-4H-pyran-3,5-dicarbonitrile 
• 138851-38-4 2-ethoxy-3,5-dicyano-6-amino-4(5-salicylyl)-4H-pyran 
• 138851-35-1 N-<5-(2,2-dicyanoethenyl)salicyloyl>dicyclohexylurea 
• 402572-22-9 4-hydroxy-3-methoxycarbonylphenylmethylenepropanenitrile 
• 402572-24-1 6-amino-1,4-dihydro-4-(4-hydroxy-3-methoxycarbonylphenyl)-3-methylpyrano[2,3-c]-pyrazole-5-carbonitrile 
• 402572-33-2 2-amino-4-(4-hydroxy-3-methoxycarbonylphenyl)-5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyran-3-carbonitrile 

Relevant articles and documents

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

THERAPEUTIC DRUG FOR DIABETES

-